iShares Biotechnology ETF
IBB
IBB
827 hedge funds and large institutions have $4.71B invested in iShares Biotechnology ETF in 2023 Q3 according to their latest regulatory filings, with 61 funds opening new positions, 165 increasing their positions, 334 reducing their positions, and 62 closing their positions.
New
Increased
Maintained
Reduced
Closed
more ownership
Funds ownership: →
less first-time investments, than exits
New positions opened: | Existing positions closed:
less funds holding
Funds holding: →
less capital invested
Capital invested by funds: $ → $
18% less funds holding in top 10
Funds holding in top 10: 11 → 9 (-2)
51% less repeat investments, than reductions
Existing positions increased: 165 | Existing positions reduced: 334
74% less call options, than puts
Call options by funds: $208M | Put options by funds: $806M
Holders
827
Holding in Top 10
9
Calls
$208M
Puts
$806M
Top Buyers
| 1 | +$160M | |
| 2 | +$48.2M | |
| 3 | +$37.3M | |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$12M |
| 5 |
Capital Fund Management (CFM)
Paris,
France
|
+$7.47M |
Top Sellers
| 1 | -$181M | |
| 2 | -$31.3M | |
| 3 | -$25.7M | |
| 4 |
E
Ergoteles
New York
|
-$24.7M |
| 5 |
JP Morgan Chase
New York
|
-$23.9M |